Clinical trial
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
NCT05883852
Study timeline
Study start (actual)2023-06-07Date precision: day
Registry last updated2023-06-27
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
HER2 Positive Early Breast Cancerunresolved
Interventions
DocetaxelDRUG · verified · RxNorm: docetaxel
carboplatinDRUG · verified · RxNorm: carboplatin
TrastuzumabDRUG · verified · RxNorm: trastuzumab
PertuzumabDRUG · verified · RxNorm: pertuzumab
EpirubicinDRUG · verified · RxNorm: epirubicin
cyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
Sponsors & collaborators
Fudan Universitylead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05883852 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.